Piramal Healthcare Ltd


BSE: 500302 | NSE: PIRHEALTH | ISIN: INE140A01024 
Market Cap: [Rs.Cr.] 7,302 | Face Value: [Rs.] 2
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

 Discuss this stock

Board Meet

03-May-12 
Piramal Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 03, 2012 to consider and approve the Audited Financial Results (consolidated & stand-alone) of the Company for the financial year ended March 31, 2012 and also to consider recommendation of dividend on the equity shares of the Company for the financial year ended March 31, 2012. Piramal Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 03, 2012, inter alia, has recommended dividend of Rs. 17.5 (Rupees Seventeen and Paise Fifty only) per equity share of face value of Rs. 2/- (i.e. @ 875%) for the financial year ended March 31, 2012. (As Per BSE Announcement Website Dated on 03/05/2012) 
02-Apr-12 
Piramal Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 02, 2012 approved the proposal to change the name of the Company from Piramal Healthcare Limited to Piramal Enterprises Limited or such other name as maybe approved by the Registrar of Companies / other statutory authorities. The proposed change in name would be subject to approvals of the shareholders and the Central Government. 
02-Feb-12 
Piramal Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 02, 2012, to consider and take on record the Unaudited Financial Results (consolidated and stand-alone) of the Company for the 3rd Quarter ended December 31, 2011. The said results shall be subjected to limited review. 
20-Oct-11 
Piramal Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 20, 2011, to consider and take on record the Financial Results (consolidated and standalone) of the Company for the 2nd quarter and half year ended September 30, 2011. Piramal Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 20, 2011, has decided to seek an enabling approval from shareholders for availing and undertaking new business opportunities, which the Company has been exploring consequent to the sale of its domestic formulations business during FY10. Accordingly, suitable objects are proposed to be inserted in the Objects Clause of the Memorandum of Association of the Company and an enabling approval of the shareholders for commencing the businesses covered there under is being sought by Postal Ballot. (As Per BSE Announcement Website Dated on 20/10/2011) 
02-Aug-11 
Piramal Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 02, 2011, inter alia, to consider and take on record the Unaudited Financial Results (consolidated and standalone) of the Company for the 1st Quarter ended June 30, 2011 (Q1). The results shall be subjected to limited review. 

AGM

19-Jul-12
Piramal Healthcare Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 11, 2012 to July 19, 2012 (both days inclusive) for the purpose of Payment of Dividend & 65th Annual General Meeting (AGM) of the Company to be held on July 19, 2012. The dividend on Equity Shares, if declared by the Members at the AGM, will be paid between July 20, 2012 and July 25, 2012. 
09-Aug-11
Piramal Healthcare Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 01, 2011 to August 09, 2011 (both days inclusive) for the purpose of Payment of Dividend & 64th Annual General Meeting (AGM) of the Company to be held on August 09, 2011. Piramal Healthcare Ltd has informed BSE that at the 64th Annual General Meeting of the Company which was held on August 09, 2011, all the businesses mentioned in the Notice convening the said meeting were transacted and all the resolutions were passed unanimously. A brief summary of the business transacted at the AGM is furnished below: - The Audited Accounts for the year ended March 31, 2011 were adopted; - Dividend at Rs. 12/- per equity share of Rs. 2/- (i.e. @ 600%) on 16,72,10,515 Equity Shares was declared for the financial year ended March 31, 2011; - Mr. Y. H. Malegam and Mr. Deepak Satwlekar have been reappointed as Directors of the Company; - M/s. Price Waterhouse, Chartered Accountants, Mumbai have been reappointed as Auditors of the Company; - Mr. Amit Chandra has bee appointed as Director of the Company. (As Per BSE Announcement Dated on 16.08.2011) 
09-Jul-10
Piramal Healthcare Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 01, 2010 to July 09, 2010 (both days inclusive) for the purpose of 63rd Annual General Meeting (AGM) of the Company to be held on July 09, 2010. Piramal Healthcare Limited has submitted to the Exchange a brief summary of the business transacted at the AGM held on July 09, 2010: 1)The Audited Accounts for the year ended March 31, 2010 were adopted; 2)Dividend at Rs. 5.40 per equity share of Rs.2/- (i.e. @ 270%) on 20,90,13,144 Equity Shares was declared for the financial year ended March 31, 2010; 3) Mr. R. A. Shah and Mr. N. Vaghul have been reappointed as Directors of the Company; 4) M/s. Price Waterhouse, Chartered Accountants, Mumbai have been reappointed as Auditors of the Company. Special Business: a) Special Resolution for payment of commission to Non-Executive Directors at the rate upto 1 percent of the net profits of the Company in each year for a further period of 5 years commencing from the Company's financial year ending March 31, 2011 was duly passed; b)Special Resolution for re-appointment of Mr. N. Santhanam as Executive Director & Chief Operating Officer, not liable to retire by rotation, for a period of 3 years with effect from October 25, 2010 was duly passed; c) Special Resolution for keeping of register and index of members and debenture-holders with the Company's Share Transfer Agents for the time being, who presently are Link Intime India Private Limited having their office at C-13, Pannalal Silk Mills Compound LBS Marg, Bhandup (West), Mumbai - 400 078 was duly passed. (As Per NSE Bulletin dated on 15.07.2010) 
18-Jun-09
Piramal Healthcare Ltd has informed BSE that the 62nd Annual General Meeting (AGM) of the Company to be held on June 18, 2009. Piramal Healthcare Ltd has informed BSE that the members at the 62nd Annual General Meeting (AGM) of the Company held on June 18, 2009, inter alia, have passed the following resolutions: 1. The Audited Accounts for the year ended March 31, 2009 were adopted. 2. Dividend at Rs 4.20 per equity share on 20,90,13,144 Equity Shares of Rs 2/- each (i.e. @ 210%) was declared for the financial year ended March 31, 2009. 3. Mr. Keki Dadiseth and Mr. S Ramadorai have been reappointed as Directors of the Company. 4. M/s. Price Waterhouse, Chartered Accountants, Mumbai have been reappointed as Auditors of the Company. 5. Special Resolution for appointment of Ms. Nandini Piramal as Executive Director and related resolution for increasing the strength of the Board from 9 to 10 (which is within the maximum limit of 20 fixed by the Articles). 6. Special Resolution for keeping of register and index of members and debenture-holders at the Company's Share Transfer Agents, Freedom Registry Ltd (formerly known as M/s. Amtrac Management services Ltd) at their administrative office, which is presently at 8, Peninsula Centre, Dr. S S Rao Road, Parel, Mumbai-400 012 and which is proposed to be shifted to Unit No. 129, Bayside Mall. 35/C, M. Malvia Marg, Tardeo Road, Haji All, Mumbai 400 034; 7. Ordinary Resolution u/s. 293 (1) (d) for increasing Borrowing Powers to Rs 1500 Crores over and above the paid up share capital and free reserves. 8. Ordinary Resolution u/s. 293 (1) (a) for mortgage / charge that may have to be created on the borrowings availed pursuant to the aforesaid resolution u/s. 293 (1) (d). (As Per BSE Announcement Website dated on 22.06.2009) 
26-Jun-08
The Company has informed that the 61st Annual General Meeting (AGM) of the Company will be held on June 26, 2008. Piramal Healthcare Ltd has informed BSE that the members at the 61 Annual General Meeting (AGM) of the Company held on June 26, 2008, inter alia, have all the resolutions passed unanimously / with overwhelming majority: 1. The Audited Accounts for the year ended 31 March, 2008 were adopted; 2. Following dividends were declared / confirmed: Confirmation of interim dividend paid on Preference Shares during FY'08 - The following interim dividend on preference shares that were paid during the year 2007-08, were confirmed as final, dividend: a) Interim Dividend @ 5% on 15,00,000 Cumulative Redeemable Preference Shares of Rs 100 each ("Series I Preference Shares") paid during the year, pro-rata from April 01, 2007 to January 09, 2008, being the date on which these preference shares have been redeemed; b) Interim Dividend @ 5% on 2,33,72,280 Cumulative Redeemable Preference Shares of Rs 10 each ("Series II Preference Shares") paid during the year, pro-rata from April 01, 2007 to January 09, 2008, being the date on which these preference shares have been redeemed. Declaration of dividend on Equity Shares: Final Dividend @ 210% on 20,90,13,144 Equity Shares of Rs 2/- each (i.e. Re 4.20 per Equity Share) was declared for the financial year ended March 31, 2008. - Mr. Y H Malegam and Mr. Deepak Satwalekar have been reappointed as Directors of the Company; - M/s. Price Waterhouse, Chartered Accountants, Mumbai have been reappointed as Auditors of the Company. (As Per BSE Announcement Website Dated on 02/07/2008) 

EGM

09-Aug-11
Piramal Healthcare Ltd has informed BSE that The Court Convened Meeting for approval of the Scheme of Arrangement for demerger of the NCE Research Unit of Piramal Life Sciences Limited ('PLSL') into the Company ('the Scheme') was duly held on August 09, 2011 and the shareholders have approved the Scheme by an overwhelming requisite majority. Piramal Healthcare Ltd has informed BSE that the shareholders at the Extra Ordinary General Meeting (EGM) of the Company held on August 09, 2011, inter alia, has approved all the business mentioned in the Notice convening the EGM by an overwhelming requisite majority. (As Per BSE Announcement Dated on 16.08.2011) 
23-Nov-07
Nicholas Piramal India Ltd pursuant to the order made by the Hon'ble High Court of Judicature at Bombay, a meeting of the Equity Shareholders of the Company will be held on November 23, 2007, for the purpose of considering and if thought fit, approving, with or without modification, the arrangements embodied in the Composite Scheme of Arrangement ("the Scheme") between the Company and NPIL Research and Development Ltd. Further the Company has informed BSE that pursuant to the order made by the Hon'ble High Court of Judicature at Bombay, a meeting of the Shareholders of the 5%- 2,33,72,280 Cumulative Redeemable Preference Shares of Rs 10 each (""the Series II Preference Shareholders") of the Company will be held on November 23, 2007, or soon after the conclusion of the meeting of the Equity Shareholders which has been convened on the same date by the Hon'ble High Court of Judicature at Bombay vide its aforesaid Order, whichever is later, for the purpose of considering and if thought fit, approving, with or without modification, the arrangements embodied in the Composite Scheme of Arrangement ("the Scheme") between the Company and NPIL Research & Development Ltd. Nicholas Piramal India Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on November 23, 2007, inter alia, to transact the following business: 1. Reduction in the paid up value of the equity shares of the Company from Re 2 per equity share to Rs 1.90 per equity share, aggregating to a total reduction of Rs 2,09,01,314 in the Equity Share Capital of the Company ("Equity Capital Reduction"), in the manner as provided in Clause 6 of the Composite Scheme of Arrangement between the Company and NPIL Research and Development Ltd ("Scheme") which is subject to sanction by the Hon'ble High Court, subject to necessary provisions & approvals. 2. Reduction in the face value of the 5% Cumulative Redeemable Preference Shares of Rs 100 each ("Series I Preference Shares") of the Company from Rs 100 per share to Rs 90 per share ("Series I Preference Share Value Reduction"), in the manner as provided in Clause 5.2.3 of the Composite Scheme of Arrangement ("Scheme") between the Company and NPIL Research and Development Ltd ("NRDL") which is subject to sanction by the Hon'ble High Court, which reduction may take place in the event of the issue of Preference Shares by NRDL to the holders of the Series I Preference Shares of the Company under Clause 5.2.1 of the Scheme, subject to necessary provisions & approvals. 3. Reduction in the face value of the 5% Cumulative Redeemable Preference Shares of Rs 10 each ("Series II Preference Shares") of the Company from Rs 10 per share to Rs 9 per share ("Series II Preference Share Value Reduction"), in the manner as provided in Clause 5.2.3 of the Composite Scheme of Arrangement ("Scheme") between the Company and NPIL Research and Development Ltd ("NRDL") which is subject to sanction by the Hon'ble High Court, which reduction may take place in the event of the issue of Preference Shares by NRDL to the holders of the Series II Preference Shares of the Company under Clause 5.2.1 of the Scheme; subject to necessary provisions & approvals. 4. In the event of allotment of Preference Shares by NRDL being made to the holders of the 15,00,000 - 5% Cumulative Redeemable Preference Shares of Rs 100 each ("Series I Preference Shares") and the holders of the 2,33,72,280 - 5% Cumulative Redeemable Preference Shares of Rs 10 each ("Series II Preference Shares") of the Company under clause 5.2.1 of the Composite Scheme of Arrangement ("Scheme") between the Company and NPIL Research and Development Ltd, resulting in the reduction in the face value of the Series I Preference Shares from Rs 100 per share to Rs 90 per share and in the face value of the Series II Preference Shares from Rs 10 per share to Rs 9 per share as contemplated under clause 5.2.3 of the Scheme, the Authorised Share Capital of the Company shall be consequently altered and the existing Clause 'V' (being Capital Clause) of the Memorandum of Association of the Company shall be substitued by the following Clause: "Clause V The Authorised Share Capital of the Company is Rs 121,16,27,720 (Rupees One hundred twenty one crores, sixteen lakhs, twenty seven thousand, seven hundred and twenty only) divided into 25,00,00,000 Equity Shares of Rs 2/- each, 15,00,000 Preference Shares of Rs 90/- each, 15,00,000 Preference Shares of Rs 100/- each, 2,33,72,280 Preference Shares of Rs 9/- each, 6,27,720 Preference Shares of Rs 10/- each and 10,50,00,000 Unclassified Shares of Rs 2/- each. Subject to the provisions of the Companies Act, 1956 ('the Act') the Board shall have power to increase or reduce the Authorised Share Capital, to classify the unclassified shares, to re-classify the classified shares, and to divide the shares so classified or re-classified in shares of several classes permissible under the Act and to attach thereto respectively such preferential, deferred, qualified and other special rights, privileges, restrictions and conditions as may be determined under the provisions of the law in force for the time being and the regulations of the Company and to vary, modify, abrogate or deal with any such rights, privileges, restrictions and conditions in the manner prescribed by the regulations of the Company and under the provisions of the law in force". Further, to alter the Article 3 of the Articles of Association of the Company by substituting the following Article in place and in lieu thereof: "Article 3 The Authorised Share Capital of the Company is Rs 121,16,27,720 (Rupees One hundred twenty one crores, sixteen lakhs, twenty seven thousand, seven hundred and twenty only) divided into 25,00,00,000 Equity Shares of Rs 2/- each, 15,00,000 Preference Shares of Rs 90/- each, 15,00,000 PreferenceShares of Rs 100/-each, 2,33,72,280 Preference Shares of Rs 9/- each, 6,27,720 Preference Shares of Rs 10/- each and 10,50,00,000 Unclassified Shares of Rs 2/- each." 5. Subject to the sanction of the Composite Scheme of Arrangement ("Scheme") between the Company and NPIL Research and Development Ltd ("NRDL") by the Hon'ble High Court of Judicature at Bombay, consent of the Company be and is hereby accorded for debiting the Securities Premium Account in the books of account of the Company pursuant to Clause 7.22 of the Scheme, the excess of book values of assets over liabilities of the Company transferred to NRDL under the Scheme, after adjusting the reduction in equity share capital referred to in clause 6.1 of the Scheme to the extent of Rs 2,09,01,314 and after giving effect to Clause 4.1.5 of the Scheme, subject to necessary provisions & approvals. 6. Re-appointment of Dr. (Mrs.) Swati A Piramal ("Dr. Piramal") as Director in Whole-time employment of the Company (designated as 'Director - Strategic Alliances & Communication'), not liable to retire by rotation, for a further period of five years with effect from November 20, 2007, on remuneration, terms & conditions. 7. Appointment of Mr. N Santhanam as a Director of the Company. 8. Appointment of Mr. N Santhanam as Director in whole-time employment of the Company (designated as "Executive Director & Chief Financial Officer") for a period of 3 years with effect from October 25, 2007, not liable retire by rotation, on remuneration, terms & conditions. Nicholas Piramal India Ltd pursuant to the meeting of the Equity Shareholders and Series II Preference Shareholders of the Company at its court convened meeting held on November 23, 2007, have approved the Composite Scheme of Arrangement between the Company and NPIL Research & Development Ltd, by overwhelming requisite majority. (As Per BSE Announcement Website Dated on 29/11/2007) Nicholas Piramal India Ltd has informed BSE that the Extraordinary General Meeting (EGM) of the Company held on November 23, 2007, inter alia, all the resolutions for the businesses mentioned in the Notices convening the said Meetings were duly passed. The summary of the businesses transacted at the said Meetings are given below: A. Business Transacted at the Extraordinary General Meeting of the Equity and Preference Shareholders - Reduction of Equity Share Capital from Rs 2 per share to Rs 1.90 per share and simultaneous capitalization of equivalent amount from General Reserves, consequent to which, the paid-up value of the Equity Shares would be retained at Rs 2 per share; - Reduction of Preference Share Capital [Series I] from Rs 100 per share to Rs 90 per share, in the event of NPIL Research & Development Ltd ("NRDL")) allotting its Preference Shares of Rs 10 each to the Series I Preference Shareholders of the Company in the ratio of 1:1, under the Scheme of Arrangement between the Company and NRDL ("the said Scheme"); - Reduction of Preference Share Capital [Series II] from Rs 10 per share to Rs 9 per share, in the event of NRDL allotting its Preference Shares of Rs 10 each to the Series II Preference Shareholders of the Company in the ratio of 1:10, under the said Scheme; - Alteration of the Authorised Preference Share Capital (Series I & II), in the event of the Reduction of the Series I & II Preference Share Capital referred to above taking effect under the said Scheme; - Utilisation of Securities Premium Account pursuant to the said Scheme; - Re-appointment of Dr. (Mrs.) Swati A Piramal as Director-Strategic Alliances & Communications for a further period of 5 years w.e.f. November 20, 2007; - Appointment of Mr. N Santhanam as Director; - Appointment of Mr. N Santhanam as Executive Director & Chief Financial Officer for a period of 3 years w.e.f. October 25, 2007; B. Business Transacted at the Extraordinary General Meeting of the Series II Preference Shareholders - Reduction of Preference Share Capital [Series II] from Rs 10 per share to Rs 9 per share; in the event of NRDL allotting its Preference Shares of Rs 10 each to the Series II Preference Shareholders of the Company in the ratio of 1:10, under the said Scheme. (As per BSE Announcement Website dated on 29/11/2007) 
08-Mar-04
The company has informed the following :- 1. The Court Convened Meeting for approval of the Scheme of Amalgamation for the merger of Canere Actives & Fine Chemicals Pvt Ltd and the Company was held on March 8, 2004 and the said Scheme has been approved by the shareholders. 2. The EGM of the shareholders of the Company which was also convened on March 8, 2004 was held immediately after the conclusion of the aforesaid Court Convened Meeting. The following business were approved by the shareholders and the resolutions were passed: (a) Approval to the increase in Authorised Share Capital of the company from Rs. 750 million to Rs. 1250 million, by creation of 2,40,00,000 Preference Shares of Rs. 10/- each, 15,00,000 Preference Shares of Rs. 100/- each and 1,10,00,000 Unclassified shares of Rs 10/- each and to the consequential amendments to the relevant clauses of the Memorandum and Articles of Association of the Company. (b) Approval under the Companies Act, 1956 to the issue and allotment by the Company of: i) 15,00,000 - 5% Cumulative Redeemable Preference Shares of Rs 100 each, credited as fully paid up, to the shareholders of CANERE, in the ration of 3:20 (i.e. 3 Preference Shares for every 20 Equity Shares held in CANERE). ii) 2,33,72,280 - 5% Cumulative Redeemable Shares of Rs 10 each, credited as fully paid up to the shareholders of Morarjee Goculdas Spg & Wvg Co. Ltd (Morarjee) in the ratio of 6:5 (i.e. 6 Preference Shares for every 5 equity shares held in Morarjee). iii) Approval under u/s 100 and 78 of the Act by special resolution, for charging and debiting to the Company's Share Premium Account, the deficit of the aggregate value of assets over the value of liabilities recorded by the Company upon their transfer to and vesting in the Company under the Scheme, after adjusting for the face value of the Preference Shares to be issued and allotted as aforesaid.  
19-Sep-03
EGM 19/09/2003 - Court Convened EGM to approve the Scheme of Arrangement. Nicholas Piramal India Ltd. has informed the Exchange that an EGM will be held on September 19, 2003 for approval of the Scheme of Arrangement between the Company and Kojam Fininvest Limited and their respective Members. (Refer NSE dated 04/09/2003) Nicholas Piramal India Ltd. has informed the Exchange regarding the Court Convened Meeting and Extra-ordinary General Meeting of the Members of the Company held on September 19, 2003. The Scheme of Arrangement ("the Scheme") between the Company and Kojam Fininvest Limited ("KOJAM") was modified by the Company by inclusion of the following clause: "The listing and admission of new equity shares of KFL issued in terms of clause 5.1 of the Scheme of Arrangement on The National Stock Exchange of India Limited, The Stock Exchange, Mumbai and The Stock Exchange, Ahmedabad is not automatic and will be subject to fulfillment of listing criteria of The National Stock Exchange of India Limited, The Stock Exchange, Mumbai and The Stock Exchange, Ahmedabad for such issues and also subject to such other terms and conditions as may be prescribed by The National Stock Exchange of India Limited, The Stock Exchange, Mumbai and The Stock Exchange, Ahmedabad at the time of KFL seeking listing". The same has been approved by the shareholders in its meeting held on September 19, 2003. In the Extra-ordinary General Meeting ("EGM") held immediately after the conclusion of the aforesaid Court Convened Meeting, the Special Resolution for seeking consent of the shareholders u/s 100 and 78 of the Companies Act 1956, for debiting to the Company's Share Premium Account the carrying cost of the Investment in Gujarat Glass Pvt. Ltd. to be transferred to KOJAM under the Modified Scheme, was unanimously approved by the shareholders. (Refer NSE dated 23/09/2003) 
13-Jan-03
Digital Globalsoft Ltd. has informed the Exchange that on January 13, 2003 the company has allotted 10,950 equity shares of Rs.10/- each to the employees who have exercised their options under the Company's Employee Stock Option Plan . With these allotments the current paid up capital of the company will be Rs.328,826,570. Outcome of EGM - Nicholas Piramal India Ltd. has informed the Exchange that at its meeting held on January 13, 2003 the following has been decided: 1) The Court Convened Meeting for approval of the scheme of amalgamation between Global Bulk Drugs & Fine Chemicals Pvt.Ltd. and the company, was duly held on January 13, 2003 and the said scheme has been approved by the shareholders with the overwhelming requisite majority. 2) At the EGM the shareholders have approved the following resolutions - a) Approval was accorded to the increase in the authorised share capital of the company from Rs.50 crs to Rs.75 by creation of 15,00,000 preference shares of Rs.100 each and 1,00,00,000 unclassified shares of Rs.10 each. b) Approval under section 81(1A) of the Companies Act, 1956 to the issue and allotment of 15,00,000 6% non cumulative redeemable preference shares of Rs.100 each, credited as fully paid up to the shareholders of GLOBAL. Also the outcome of EGM in the ratio of 3 preference shares of the company for every 88 equity shares held by them in GLOBAL. c) Approval under sections 198,269,309 read with Schedule XIII and other applicable provisions of the Act to the re-appointment of Dr. (Mrs) Swati A. Piramal as Director in whole-time employment of the company, designated as 'Director - Strategic Alliances & Communications'.  

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Sun Pharma.Inds. 59,024.02 36.91 8.84 29.33 22.3 23.3 0.01
Dr Reddy's Labs 28,898.96 31.67 4.30 22.23 15.0 15.2 0.17
Cipla 24,889.90 22.14 3.32 18.79 15.4 17.9 0.04
Ranbaxy Labs. 22,222.51 17.79 11.55 0.00 0.0 0.0 1.22
Cadila Health. 15,284.86 23.25 6.00 21.79 32.9 27.5 0.31
Glenmark Pharma. 9,637.92 36.32 4.41 24.56 11.3 11.9 0.51
Wockhardt 8,617.31 29.96 71.71 39.85 0.0 0.0 3.18
Piramal Health 7,302.32 55.83 0.66 0.33 4.2 6.1 0.07
Torrent Pharma. 5,414.83 14.93 4.15 11.43 29.5 25.9 0.55
Biocon 4,322.00 16.91 2.06 11.21 26.2 26.8 0.10
Ipca Labs. 4,270.28 15.69 4.05 10.26 26.5 25.1 0.51
Strides Arcolab 3,982.81 61.55 2.94 16.20 5.1 5.7 0.97
Aurobindo Pharma 3,357.84 10.43 1.31 8.01 26.5 19.7 0.95
Matrix Labs. 3,273.19 8.13 2.00 0.00 28.9 27.4 0.52
Fres.Kabi Onco. 2,187.12 83.79 4.04 16.45 9.5 10.8 0.58

Futures & Options Quote

 
Expiry Date
419.95 5.15  [1.2]%
Instrument: FUTSTK
Expiry Date: 31 May 2012
Open Price: 421.25
Average Price: 422.57
No. of Contracts Traded: 18,000
Open Interest: 1,068,000
Underlying: PIRHEALTH
Market Lot: 500
Previous Close: 425.10
Day’s High | Low: 421.25 | 419.95
Turnover (Cr.): 0.76
Open Int. Change: 9,000.00 (0.9% )
View detailed F& O quotes >>

Key Information

Key Executives:

Ajay G Piramal , Chairman 

Keki Dadiseth , Director 

Swati A Piramal , Executive Director 

Nandini Piramal , Executive Director 


Company Head Office / Quarters:
Piramal Tower,
Ganpatrao Kadam Mg Lower Parel,
Mumbai,
Maharashtra-400013
Phone : 91-22-30466666
Fax : 91-22-24902363
E-mail : complianceofficer.phl@piramal.com
Web : http://www.piramalhealthcare.com
Registrars:
Link Intime India Pvt Ltd
C-13 Pannalal Silk
Mills Cmpd LBS Marg
Bhandup West
Mumbai - 400 078

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
IPO
listNo IPO today
Economic Events
list U. of Michigan Confidence
list Italian Hourly Wages (MoM)
Results
list Reliance Infra. | Crompton Greaves | ITC | Guj Fluorochem